BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16393310)

  • 1. Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border.
    Cardenas VM; Graham DY; El-Zimaity HM; Opekun AR; Campos A; Chavez A; Guerrero L
    Aliment Pharmacol Ther; 2006 Jan; 23(2):295-301. PubMed ID: 16393310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease--A pilot study.
    Lüth S; Teyssen S; Kölbel CB; Singer MV
    Z Gastroenterol; 2001 Apr; 39(4):279-81, 284-5. PubMed ID: 11367976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication.
    Sharara AI; Chaar HF; Aoun E; Abdul-Baki H; Araj GF; Kanj SS
    Helicobacter; 2006 Aug; 11(4):231-6. PubMed ID: 16882325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a triple therapy with rabeprazole, amoxicillin, and faropenem as second-line treatment after failure of initial Helicobacter pylori eradication therapy.
    Togawa J; Inamori M; Fujisawa N; Takahashi H; Yoneda M; Kawamura H; Abe Y; Kirikoshi H; Kobayashi N; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
    Hepatogastroenterology; 2005; 52(62):645-8. PubMed ID: 15816496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.
    Stack WA; Knifton A; Thirlwell D; Cockayne A; Jenkins D; Hawkey CJ; Atherton JC
    Am J Gastroenterol; 1998 Oct; 93(10):1909-13. PubMed ID: 9772054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment with omeprazole, clarithromycin and amoxicillin over 6 days in patients with Helicobacter pylori-infected duodenal ulcer].
    García-Romero E; del Val A; Garrigues V; Cuquerella J; Higón MD; Barrachina M; Pons V; Bixquert M; Ponce J
    Gastroenterol Hepatol; 1999 Jan; 22(1):1-6. PubMed ID: 10089703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin.
    Sontag SJ; O'Connell S; Schnell T; Chejfec G; Seidel J; Sonnenberg A
    Am J Gastroenterol; 2001 May; 96(5):1390-5. PubMed ID: 11374672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication.
    Giannini EG; Bilardi C; Dulbecco P; Mamone M; Santi ML; Testa R; Mansi C; Savarino V
    Aliment Pharmacol Ther; 2006 Jan; 23(2):281-7. PubMed ID: 16393308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients.
    Wong WM; Huang J; Xia HH; Fung FM; Tong TS; Cheung KL; Ho VY; Lai KC; Chan CK; Chan AO; Hui CK; Lam SK; Wong BC
    J Gastroenterol Hepatol; 2005 Jun; 20(6):935-40. PubMed ID: 15946144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication: 7 vs. 14 day treatment.
    Bosques-Padilla FJ; Garza-González E; Calderón-Lozano IE; Reed-SanRoman G; de Ariño Suárez M; Valdovinos-Díaz MA; Orozco-Gámiz A; Blancas-Valencia JM; Tamayo-de la Cuesta JL
    Helicobacter; 2004 Oct; 9(5):417-21. PubMed ID: 15361080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
    Miki I; Aoyama N; Sakai T; Shirasaka D; Wambura CM; Maekawa S; Kuroda K; Tamura T; Kita T; Sakaeda T; Okumura K; Kasuga M
    Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):27-33. PubMed ID: 12544691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin, and amoxicillin in the treatment of Helicobacter pylori infection.
    Mansour NM; Hashash JG; El-Halabi M; Ghaith O; Maasri K; Sukkarieh I; Malli A; Sharara AI
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):865-70. PubMed ID: 21811161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
    Furuta T; Shirai N; Xiao F; Takashita M; Sugimoto M; Kajimura M; Ohashi K; Ishizaki T
    Hepatogastroenterology; 2003; 50(54):2274-8. PubMed ID: 14696516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand.
    Kongchayanun C; Vilaichone RK; Pornthisarn B; Amornsawadwattana S; Mahachai V
    Helicobacter; 2012 Aug; 17(4):282-5. PubMed ID: 22759328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study.
    Oh HS; Lee DH; Seo JY; Cho YR; Kim N; Jeoung SH; Kim JW; Hwang JH; Park YS; Lee SH; Shin CM; Cho HJ; Jung HC; Song IS
    J Gastroenterol Hepatol; 2012 Mar; 27(3):504-9. PubMed ID: 21916989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
    Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
    Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study.
    Lim JH; Lee DH; Choi C; Lee ST; Kim N; Jeong SH; Kim JW; Hwang JH; Park YS; Lee SH; Shin CM; Jo HJ; Jang ES; Song Is; Jung HC
    Helicobacter; 2013 Jun; 18(3):180-6. PubMed ID: 23305083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of Helicobacter pylori eradication: is poor compliance the main cause?
    Wermeille J; Cunningham M; Dederding JP; Girard L; Baumann R; Zelger G; Buri P; Metry JM; Sitavanc R; Gallaz L; Merki H; Godin N
    Gastroenterol Clin Biol; 2002 Mar; 26(3):216-9. PubMed ID: 11981460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication.
    Hsu PI; Lai KH; Lin CK; Chen WC; Yu HC; Cheng JS; Tsay FW; Wu CJ; Lo CC; Tseng HH; Yamaoka Y; Chen JL; Lo GH
    Am J Gastroenterol; 2005 Nov; 100(11):2387-92. PubMed ID: 16279889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.